BMS-986218 (Bristol-Myers Squibb)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameBMS-986218 (Bristol-Myers Squibb)
Drug Alias NameAnti-CTLA4 (Bristol-Myers Squibb)BMS-986218
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CTLA4
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyColumbia University
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsProstatic Neoplasms
Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantLung Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A